[1. Parisi R, Symmons D, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013;133(2):377-85.10.1038/jid.2012.339]Search in Google Scholar
[2. Nijsten T, Looman CW, Stern RS. Clinical severity of psoriasis in last 20 years of PUVA study. Arch Dermatol 2007;143(9):1113-21.10.1001/archderm.143.9.1113]Search in Google Scholar
[3. Ghoreschi K, Weigert C, Röcken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 2007;25:574-80.10.1016/j.clindermatol.2007.08.012]Search in Google Scholar
[4. Davidovici BB, Sattar N, Prinz J, Puig L, Emery P, Barker JN, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010;130(7):1785-96.10.1038/jid.2010.103]Search in Google Scholar
[5. Armstrong AW, Callis Duffin K, Garg A, Gelfand JM, Gottlieb AB, Krueger GG, et al. Exploring priority research areas in psoriasis and psoriatic arthritis from dermatologists’ perspective: a report from the GRAPPA 2011: annual meeting. J Rheumatol 2012;39(11):2204-10.10.3899/jrheum.120825]Search in Google Scholar
[6. Feinstein AR. Th e pretherapeutic classification of comorbidity in chronic disease. J Chronic Dis 1970;23:455-568.10.1016/0021-9681(70)90054-8]Search in Google Scholar
[7. Klein DN, Riso LP. Psychiatric disorders: problems of boundaries and comorbidity. In: Costello CG, editor. Basic issues in psychopathology. New York: Guilford; 1993. p. 19-66.]Search in Google Scholar
[8. Pearce DJ, Morrison AE, Higgins KB, Crane MM, Balkrishnan R, Fleischer AB Jr, et al. Th e comorbid state of psoriasis patients in a university dermatology practice. J Dermatol Treat 2005;16(5-6):319-23.10.1080/0954663050033597716428152]Search in Google Scholar
[9. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296(14):1735-41.10.1001/jama.296.14.173517032986]Search in Google Scholar
[10. Kaye JA, Li L, Jick SS. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 2008;159(4):895-902.10.1111/j.1365-2133.2008.08707.x18616778]Search in Google Scholar
[11. Zachariae R, Zachariae H, Blomqvist K, Davidsson S, Molin L, Mork C, et al. Self-reported stress reactivity and psoriasisrelated stress of Nordic psoriasis sufferers. J Eur Acad Dermatol Venereol 2004;18(1):27-36.10.1111/j.1468-3083.2004.00721.x14678528]Search in Google Scholar
[12. Bhole VM, Choi HK, Burns LC, Vera Kellet C, Lacaille DV, Gladman DD, et al. Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. Rheumatology (Oxford) 2012;51(3):552-6.10.1093/rheumatology/ker349]Search in Google Scholar
[13. Cheng J, Kuai D, Zhang L, Yang X, Qiu B. Psoriasis increased the risk of diabetes: a meta-analysis. Arch Dermatol Res 2012;304(2):119-25.10.1007/s00403-011-1200-6]Search in Google Scholar
[14. Dreiher J, Weitzman D, Cohen AD. Psoriasis and osteoporosis: a sex-specifi c association? J Invest Dermatol 2009;129(7):1643-9.]Search in Google Scholar
[15. Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. Th e risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006;126(10):2194-201.10.1038/sj.jid.5700410]Search in Google Scholar
[16. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatol Treat. 2008;19(1):5-21.10.1080/09546630701364768]Search in Google Scholar
[17. Mussi A, Bonifati C, Carducci M, D`Agosto G, Pimpinelli D, D`Urso D, et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents 1997;11(3):115-8.]Search in Google Scholar
[18. Wakkee M, Th io HB, Prens EP, Sijbrands EJ, Neumann HA. Unfavorable cardiovascular risk profi les in untreated and treated psoriasis patients. Atherosclerosis 2007;190(1):1-9.10.1016/j.atherosclerosis.2006.07.011]Search in Google Scholar
[19. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefi ts and risks. Br J Dermatol 2005;52:597-615.10.1111/j.1365-2133.2005.06563.x]Search in Google Scholar
[20. Gisondi P, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M, et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. J Eur Acad Dermatol Venereol 2013;27(1):e30-41.10.1111/j.1468-3083.2012.04450.x]Search in Google Scholar
[21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.10.1016/0021-9681(87)90171-8]Search in Google Scholar
[22. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985;13:450-6.10.1016/S0190-9622(85)70188-0]Search in Google Scholar
[23. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3(1):55-78.10.1016/0049-0172(73)90035-8]Search in Google Scholar
[24. Executive summary of the third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97.10.1001/jama.285.19.248611368702]Search in Google Scholar
[25. Samarasekera E, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in people with psoriasis: a systematic review and meta-analysis. J Invest Dermatol In press, doi: 10.1038/jid.2013.149.10.1038/jid.2013.14923528816]Search in Google Scholar
[26. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296(14):1735-41.10.1001/jama.296.14.173517032986]Search in Google Scholar
[27. Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19(3):225-30.10.1023/B:EJEP.0000020447.59150.f9]Search in Google Scholar
[28. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc 2013;2(2):PMID 23447749.10.1161/JAHA.113.000062364727823557749]Search in Google Scholar
[29. Stern RS, Lange R. Cardiovascular disease, cancer, and cause of death in patients with psoriasis: 10 years prospective experience in a cohort of 1,380 patients. J Invest Dermatol 1988;91(3):197-201.10.1111/1523-1747.ep124648473411140]Search in Google Scholar
[30. Jensen P, Th yssen JP, Zachariae C, Hansen PR, Linneberg A, Skov L. Cardiovascular risk factors in subjects with psoriasis: a cross-sectional general population study. Int J Dermatol 2013;52(6):681-3.10.1111/j.1365-4632.2011.05408.x22512330]Search in Google Scholar
[31. Maradit-Kremers H, Dierkhising RA, Crowson CS, Icen M, Ernste FC, McEvoy MT. Risk and predictors of cardiovascular disease in psoriasis: a population-based study. Int J Dermatol 2013;52(1):32-40.10.1111/j.1365-4632.2011.05430.x353917023278607]Search in Google Scholar
[32. Brauchli YB, Jick SS, Curtin F, Meier CR. Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study. Br J Dermatol 2008;158(6):1299-307.10.1111/j.1365-2133.2008.08563.x18410416]Search in Google Scholar
[33. Wakkee M, van der Linden M, Nijsten T. Psoriasis appears not to be directly related with using cardiovascular and antidiabetic drugs. J Invest Dermatol 2008;128:2548.]Search in Google Scholar
[34. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and metaanalysis. JAMA Dermatol. 2013;149(1):84-91.10.1001/2013.jamadermatol.40623407990]Search in Google Scholar
[35. Cheng J, Kuai D, Zhang L, Yang X, Qiu B. Psoriasis increased the risk of diabetes: a meta-analysis. Arch Dermatol Res 2012;304(2):119-25.10.1007/s00403-011-1200-622210176]Search in Google Scholar
[36. Shapiro J, Cohen AD, David M, Hodak E, Chodik G, Viner A, et al. Th e association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007;56(4):629-34.10.1016/j.jaad.2006.09.01717157411]Search in Google Scholar
[37. Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol 2008;159(6):1331-7.10.1111/j.1365-2133.2008.08814.x18782318]Search in Google Scholar
[38. Cohen AD, Dreiher J, Shapiro Y, Vidavsky L, Vardy DA, Davidovici B, et al. Psoriasis and diabetes: a populationbased cross-sectional study. J Eur Acad Dermatol Venereol 2008;22:585-9.10.1111/j.1468-3083.2008.02636.x18331320]Search in Google Scholar
[39. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125:61-7.10.1111/j.0022-202X.2005.23681.x15982303]Search in Google Scholar
[40. Kim GW, Park HJ, Kim HS, Kim Sh, Ko HC, Kim BS, et al. Analysis of cardiovascular risk factors and metabolic syndrome in korean patients with psoriasis. Ann Dermatol 2012;24(1):11-510.5021/ad.2012.24.1.11328384322363149]Search in Google Scholar
[41. International Diabetes Federation [homepage on the Internet], [cited 2013 Jan 18]. Available from: http://www.idf.org.]Search in Google Scholar
[42. Gisondi P, Tessari G, Conti A, Piaserico S, Shianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007;157(1):68-73.10.1111/j.1365-2133.2007.07986.x17553036]Search in Google Scholar
[43. Nisa N, Qazi MA. Prevalence of metabolic syndrome in patients with psoriasis. Indian J Dermatol Venereol Leprol 2010;76(6):662-5.10.4103/0378-6323.7246221079309]Search in Google Scholar
[44. Tekin NS, Tekin IO, Barut F, Sipahi EY. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm 2007;2007:ID 78454.10.1155/2007/78454180429717497039]Search in Google Scholar
[45. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006;298(7):321-8.10.1007/s00403-006-0703-z17021763]Search in Google Scholar
[46. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55(5):829-35.10.1016/j.jaad.2006.08.04017052489]Search in Google Scholar
[47. Gerdes S, Zahl VA, Knopf H, Weichenthal M, Mrowietz U. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 2008;159:1116-23.10.1111/j.1365-2133.2008.08786.x18717681]Search in Google Scholar
[48. Minov J, Karadžinska-Bislimovska J, Vasilevska K, Nelovska Z, Risteska-Kuc S, Stoleski S, et al. Smoking among Macedonian workers five years after the anti-smoking campaign. Arh Hig Rada Toksikol 2012;63(2):207-13. 10.2478/10004-1254-63-2012-215022728803]Search in Google Scholar